CAMBRIDGE, Mass.--(BUSINESS WIRE)--Neurovance, Inc. today announced acceptance of its Investigational New Drug (IND) application for EB-1020 SR by the US Food and Drug Administration and initiation of a phase 2a pilot study in adult patients with attention deficit hyperactivity disorder (ADHD). EB-1020 SR was designed for use in all subtypes of adult ADHD and is intended to show greater efficacy than atomoxetine, the only non-stimulant currently approved for adults today. EB-1020 SR has the potential for less abuse liability than the stimulants, the leading medications used to treat adults with ADHD. Patient recruitment is now underway in the phase 2a clinical trial, and top-line results are expected in early 2014.
Help employers find you! Check out all the jobs and post your resume.
